Skip to main content

Table 4 Budget impact of orphan drugs in European countries

From: Impact of orphan drugs on Latvian budget

Country Budget impact of OD relative to the total drug expenditure Budget impact of OD (million EUR) Year Number of OD with active MA in the EUa Population (million)a [26] GDP (PPP) per capitaa [31] OD expenditure per 100 000 inhabitants (EUR)a
UK 1.0 % [3] 162.0 2007 44 61.32 37 507 264 188
Italy 1.5 % [3] 235.5 2007 44 58.44 33 731 402 977
Spain 2.0 % [3] 256.0 2007 44 45.23 32 807 565 996
Germany 2.1 % [3] 525.0 2007 44 82.27 36 782 638 143
Belgium 1.9 % [16, 17] 66.2 2008 49 10.71 37 847 618 114
Netherlands 4.2 % [12] 260.4 2012 64 16.75 46 379 1 554 627
France 3.1 % [13] 1054.0 2012 64 65.64 37 256 1 605 728
Sweden 2.5 % [13] 107.2 2012 64 9.52 43 869 1 126 050
Latvia 0.84 % 2.64 2014 78 1.99 22 873 132 663
  1. OD orphan drugs, MA marketing authorization, GDP (PPP) per capita gross domestic product per capita based on purchasing power parity
  2. aIn the year of interest